Get the Stockscreener App
2.43
13.02%
0.28
Skye Bioscience Inc stock is traded at $2.43, with a volume of 339.09K.
It is up +13.02% in the last 24 hours and up +31.00% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$2.15
Open:
$2.17
24h Volume:
339.09K
Relative Volume:
0.50
Market Cap:
$61.35M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-2.9001
EPS:
-0.8379
Net Cash Flow:
$-22.47M
1W Performance:
+22.73%
1M Performance:
+31.00%
6M Performance:
-34.68%
1Y Performance:
-78.53%
1-Day Range:
$2.17
$2.48
1-Week Range:
$1.99
$2.48
52-Week Range:
$1.14
$11.20
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.40 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1495 | 337.87M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.79 | 118.85M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
40.56 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Purchased by Deutsche Bank AG - Defense World
Deutsche Bank AG Purchases 32,054 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (NASDAQ:SKYE) Shares Up 24%Still a Buy? - MarketBeat
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by BNP Paribas Financial Markets - Defense World
BNP Paribas Financial Markets Has $90,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Northern Trust Corp Sells 5,170 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by Northern Trust Corp - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Should You Buy? - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Here’s What Happened - Defense World
Skye Bioscience’s SWOT analysis: obesity drug stock poised for pivotal data - Investing.com Nigeria
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $923,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Arecor CEO on Skye Bioscience partnership and the value of collaborations - Proactive financial news
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire Inc.
Skye Bioscience’s (SKYE) Outperform Rating Reiterated at William Blair - Defense World
Skye Bioscience (NASDAQ:SKYE) Earns Outperform Rating from William Blair - Defense World
Ensign Peak Advisors Inc Has $2.17 Million Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Protagenic and Phytanix merger prompts a stock surge - BioWorld MedTech
Skye Bioscience Establishes Partnership with Arecor Therapeutics - GuruFocus
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience - Proactive financial news
Arecor partners with Skye Bioscience to improve formulation of obesity drug - Proactive financial news
Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment - Nasdaq
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - The Manila Times
Skye Bioscience Establishes Partnership with Arecor - GlobeNewswire
New Obesity Drug Breakthrough: Skye Bioscience's Once-Weekly Treatment Gets Powerful Upgrade - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World
Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan
Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus
Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World
Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus
Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa
Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com
Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):